[Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)]. 1982

J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin

The pharmacokinetics of mezlocillin after intravenous infusion of 5 g over 30 minutes was compared in 15 patients divided into 3 groups. Group I patients had normal renal function, group II patients had moderate chronic renal impairment and group III patients were under haemodialysis. Plasma mezlocillin levels were measured by the microbiological method. Plasma kinetic values were calculated from a linear two-compartment model, using global estimation of macroconstants by the non-linear least square method. The elimination half-life was 1.19 +/- 0.107 h in group I patients 1.98 +/- 0.19 h in group II patients and 2.34 +/- 0.11 h in group III patients. Renal impairment did not significantly alter the apparent volume of distribution but influenced the total plasma clearance which was 139 +/- 9 ml/min, 87 +/- 9 ml/min and 61 +/- 8 ml/min in groups I, II and III patients respectively. There was a slight decrease of V1 (central compartment) and a noticeable increase of V2 (peripheral compartment), depending on the degree of renal impairment. The total volume of distribution (V1 + V2) remained relatively constant between 12 and 14 litres. Homogeneous results were obtained in each group of patients, thus confirming the regularity of the mezlocillin kinetic model at the dose administered. This should enable dosage adjustment according to renal function, as assessed by laboratory criteria.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008802 Mezlocillin Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bay-f 1353,Baypen,Melocin,Meslocillin,Mezlin,Mezlocillin Sodium,Mezlocilline,Bay f 1353,Bayf 1353,Sodium, Mezlocillin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
February 1982, La Nouvelle presse medicale,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
August 1978, Deutsche medizinische Wochenschrift (1946),
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
June 1978, Deutsche medizinische Wochenschrift (1946),
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
November 1979, Antimicrobial agents and chemotherapy,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
January 1982, The Journal of antimicrobial chemotherapy,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
July 1975, MMW, Munchener medizinische Wochenschrift,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
January 1982, The Journal of antimicrobial chemotherapy,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
January 1979, Arzneimittel-Forschung,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
May 1987, Antimicrobial agents and chemotherapy,
J P Cano, and J P Rigault, and M J Gevaudan, and S Saingra, and A Murisasco, and J Charpin
September 1977, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!